Sage Therapeutics (SAGE) Scheduled to Post Earnings on Thursday

Sage Therapeutics (NASDAQ:SAGE) will be announcing its earnings results before the market opens on Thursday, April 25th. Analysts expect the company to announce earnings of ($1.58) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($1.28) by $0.73. The business had revenue of $77.97 million for the quarter, compared to the consensus estimate of $60.15 million. Sage Therapeutics had a negative net margin of 626.32% and a negative return on equity of 54.41%. The company’s revenue was up 2621.5% compared to the same quarter last year. During the same period in the prior year, the firm earned ($2.47) earnings per share. On average, analysts expect Sage Therapeutics to post $-6 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Sage Therapeutics Trading Down 19.6 %

SAGE stock opened at $12.57 on Thursday. Sage Therapeutics has a 1-year low of $10.92 and a 1-year high of $59.99. The company’s 50 day moving average is $20.06 and its 200 day moving average is $20.96. The stock has a market cap of $755.58 million, a price-to-earnings ratio of -1.39 and a beta of 0.86.

Institutional Trading of Sage Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. MetLife Investment Management LLC acquired a new stake in shares of Sage Therapeutics in the 1st quarter worth $34,000. KBC Group NV acquired a new stake in shares of Sage Therapeutics during the 4th quarter valued at approximately $28,000. XTX Topco Ltd acquired a new position in shares of Sage Therapeutics during the 1st quarter worth approximately $209,000. Tower Research Capital LLC TRC raised its position in shares of Sage Therapeutics by 74.0% during the 3rd quarter. Tower Research Capital LLC TRC now owns 5,050 shares of the biopharmaceutical company’s stock worth $104,000 after purchasing an additional 2,148 shares during the last quarter. Finally, Commonwealth Equity Services LLC purchased a new stake in Sage Therapeutics in the 2nd quarter worth approximately $241,000. 99.22% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

SAGE has been the subject of a number of research analyst reports. Royal Bank of Canada raised their price target on Sage Therapeutics from $21.00 to $26.00 and gave the stock a “sector perform” rating in a research note on Thursday, February 15th. JPMorgan Chase & Co. raised their price target on Sage Therapeutics from $24.00 to $29.00 and gave the company an “overweight” rating in a report on Tuesday, March 26th. Bank of America downgraded Sage Therapeutics from a “neutral” rating to an “underperform” rating and reduced their price objective for the stock from $24.00 to $14.00 in a report on Wednesday. HC Wainwright reissued a “neutral” rating and issued a $28.00 target price on shares of Sage Therapeutics in a research report on Wednesday. Finally, StockNews.com raised Sage Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, February 15th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, Sage Therapeutics presently has a consensus rating of “Hold” and an average price target of $40.56.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.